“Repeat-dose toxicity in rats and cynomolgus monkeys have been conducted, 2-week studies with a 4-week recovery period, and 4-week studies in both species.”
Pharmacokinetics: rat and monkey both form the metabolites GS-704277 and GS-441524
“Pharmacokinetic studies supported the selection of the rat and monkey for the assessment of RDV toxicology. Both rat and monkey formed the intermediate metabolite GS-704277 and the nucleoside metabolite GS-441524.”
✓ VerifiedFDA pharmacology/toxicology review, p. 8Source ↗
Surrogate molecule
No surrogate; the clinical compound was tested
“Intravenous administration (slow bolus) of remdesivir to rats at dosage levels of ≥3 mg/kg/day for up to 4 weeks resulted in findings indicative of kidney injury and/or dysfunction.”
✓ VerifiedFDA pharmacology/toxicology review, p. 11Source ↗